株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心筋症:パイプライン分析

Cardiomyopathy - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 253651
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
心筋症:パイプライン分析 Cardiomyopathy - Pipeline Review, H2 2015
出版日: 2015年09月23日 ページ情報: 英文 119 Pages
概要

心筋症は、心筋の異常による疾患です。運動または安静時の息切れ、脚・足首・足のむくみ、咳、倦怠感、めまい、立ちくらみ、失神などの症状が見られます。危険因子は、家族歴、肥満、アルコール依存症、糖尿病、がん治療などです。治療には、利尿薬、β遮断薬、アンジオテンシン変換酵素(ACE)阻害薬などが含まれます。

当レポートでは、心筋症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

心筋症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Array BioPharma Inc.
  • Bioheart, Inc.
  • Gilead Sciences, Inc.
  • Heart Metabolics Limited
  • Hemostemix Ltd
  • Kasiak Research Private Limited
  • miRagen Therapeutics, Inc.
  • MyoKardia, Inc.
  • Neurimmune Holding AG
  • Nyken BV
  • Sanofi
  • Shire Plc
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Private Limited
  • Torrent Pharmaceuticals Limited
  • Vericel Corporation
  • Virocan Therapeutics Private Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ACP-01
  • AdipoCell
  • AmVidcm-008
  • ARRY-797
  • binimetinib
  • CAP-1002
  • Cyndacel-M
  • 拡張型心筋症治療薬
  • 糖尿病性心筋症・代謝性疾患向けNrf2活性化薬
  • eleclazine
  • 心筋症向け遺伝子治療
  • 高血圧性心筋症・腎臓の線維症向けSmad7活性化遺伝子治療
  • ixmyelocel-T
  • JR-100
  • 間充織幹細胞
  • MGN-9103
  • 循環器系疾患向けモノクローナル抗体
  • MYK-461
  • NI-301
  • NYK-1112
  • perhexiline maleate
  • 心筋症向けGLP-1作動用遺伝子組み換え型ペプチド
  • 心筋症・虚血再かん流傷害向けInterleukin-1受容体拮抗用遺伝子組み換え型タンパク質
  • Refacell-DCM
  • SHP-627
  • 拡張型心筋症向け小分子
  • Stempeucel
  • TRC-120038
  • YS-1402

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7090IDB

Summary

Global Markets Direct's, 'Cardiomyopathy - Pipeline Review, H2 2015', provides an overview of the Cardiomyopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cardiomyopathy Overview
  • Therapeutics Development
    • Pipeline Products for Cardiomyopathy - Overview
    • Pipeline Products for Cardiomyopathy - Comparative Analysis
  • Cardiomyopathy - Therapeutics under Development by Companies
  • Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes
  • Cardiomyopathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cardiomyopathy - Products under Development by Companies
  • Cardiomyopathy - Products under Investigation by Universities/Institutes
  • Cardiomyopathy - Companies Involved in Therapeutics Development
    • Array BioPharma Inc.
    • Bioheart, Inc.
    • Gilead Sciences, Inc.
    • Heart Metabolics Limited
    • Hemostemix Ltd
    • Kasiak Research Private Limited
    • miRagen Therapeutics, Inc.
    • MyoKardia, Inc.
    • Neurimmune Holding AG
    • Nyken BV
    • Sanofi
    • Shire Plc
    • Stemedica Cell Technologies, Inc.
    • Stempeutics Research Private Limited
    • Torrent Pharmaceuticals Limited
    • Vericel Corporation
    • Virocan Therapeutics Private Limited
  • Cardiomyopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmVidcm-008 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARRY-797 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eleclazine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JR-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mesenchymal Stem Cells - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-9103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MYK-461 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NYK-1112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • perhexiline maleate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide to Agonize GLP-1 for Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Refacell-DCM - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-627 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stempeucel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-120038 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YS-1402 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cardiomyopathy - Recent Pipeline Updates
  • Cardiomyopathy - Dormant Projects
  • Cardiomyopathy - Dormant Projects
  • Cardiomyopathy - Discontinued Products
  • Cardiomyopathy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy
      • Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
      • Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
      • Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy
      • Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
      • Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
      • Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure
      • Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
      • Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
      • Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cardiomyopathy, H2 2015
  • Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2015
  • Cardiomyopathy - Pipeline by Bioheart, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Gilead Sciences, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Heart Metabolics Limited, H2 2015
  • Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2015
  • Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2015
  • Cardiomyopathy - Pipeline by miRagen Therapeutics, Inc., H2 2015
  • Cardiomyopathy - Pipeline by MyoKardia, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Neurimmune Holding AG, H2 2015
  • Cardiomyopathy - Pipeline by Nyken BV, H2 2015
  • Cardiomyopathy - Pipeline by Sanofi, H2 2015
  • Cardiomyopathy - Pipeline by Shire Plc, H2 2015
  • Cardiomyopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Stempeutics Research Private Limited, H2 2015
  • Cardiomyopathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
  • Cardiomyopathy - Pipeline by Vericel Corporation, H2 2015
  • Cardiomyopathy - Pipeline by Virocan Therapeutics Private Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2015
  • Cardiomyopathy - Dormant Projects, H2 2015
  • Cardiomyopathy - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Cardiomyopathy, H2 2015
  • Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top